The range of medicines available is extensive, covering various therapeutic areas. While the focus is on essential medicines, the scheme also includes drugs for chronic conditions like diabetes, hypertension, and cardiovascular diseases, as well as antibiotics, pain relievers, and anti-infectives. The aim is to cover a significant portion of the population's medicinal needs.

The pricing mechanism is fixed by the government. The maximum retail price (MRP) for Jan Aushadhi medicines is set at a level that is significantly lower than the MRP of branded generics. This is achieved by keeping overheads low and eliminating marketing and branding costs associated with private players. The profit margins for the kendra operators are also regulated.

The recent news about the Hormuz crisis impacting raw material costs for pharmaceuticals, as reported, directly affects the supply chain for all drug manufacturers, including those supplying to Jan Aushadhi. While Jan Aushadhi aims to keep prices low, a sharp increase in the cost of APIs and packaging materials, as seen with paracetamol and other drugs, can put pressure on the procurement costs for the scheme. However, the government's bulk procurement and fixed pricing strategy are designed to absorb some of these fluctuations and protect consumers from sudden price hikes, unlike fixed-price government contracts mentioned in the news which can trap smaller manufacturers.

A common exam trap is assuming Jan Aushadhi only sells very basic medicines. In reality, the scheme has expanded to include a wide array of drugs, including those for lifestyle diseases and critical illnesses, making it a comprehensive solution for affordable healthcare. Another trap is believing that quality is compromised; the government ensures strict quality checks.

The scheme's success is measured by its reach and impact on medicine expenditure. As of recent reports, there are over 9,0009,000 Jan Aushadhi Kendras operational across India, and the scheme has saved citizens an estimated ₹10,000 crore₹10,000 crore annually. This quantitative impact is crucial for exam answers.

The scheme is a direct manifestation of the government's commitment to the Directive Principles of State PolicyDirective Principles of State Policy, particularly Article 4747, which mandates the state to improve public health. It aligns with the broader goal of achieving universal health coverage and ensuring that essential medicines are a public good, not just a commodity.

UPSC examiners often test the understanding of the scheme's objectives, its operational model (PMJAKs), the quality assurance mechanisms, and its impact on affordability and accessibility. They might ask about the difference between Jan Aushadhi and branded generics, or the challenges faced by the scheme, such as supply chain disruptions or ensuring consistent quality from all suppliers.

The range of medicines available is extensive, covering various therapeutic areas. While the focus is on essential medicines, the scheme also includes drugs for chronic conditions like diabetes, hypertension, and cardiovascular diseases, as well as antibiotics, pain relievers, and anti-infectives. The aim is to cover a significant portion of the population's medicinal needs.

The pricing mechanism is fixed by the government. The maximum retail price (MRP) for Jan Aushadhi medicines is set at a level that is significantly lower than the MRP of branded generics. This is achieved by keeping overheads low and eliminating marketing and branding costs associated with private players. The profit margins for the kendra operators are also regulated.

The recent news about the Hormuz crisis impacting raw material costs for pharmaceuticals, as reported, directly affects the supply chain for all drug manufacturers, including those supplying to Jan Aushadhi. While Jan Aushadhi aims to keep prices low, a sharp increase in the cost of APIs and packaging materials, as seen with paracetamol and other drugs, can put pressure on the procurement costs for the scheme. However, the government's bulk procurement and fixed pricing strategy are designed to absorb some of these fluctuations and protect consumers from sudden price hikes, unlike fixed-price government contracts mentioned in the news which can trap smaller manufacturers.

A common exam trap is assuming Jan Aushadhi only sells very basic medicines. In reality, the scheme has expanded to include a wide array of drugs, including those for lifestyle diseases and critical illnesses, making it a comprehensive solution for affordable healthcare. Another trap is believing that quality is compromised; the government ensures strict quality checks.

The scheme's success is measured by its reach and impact on medicine expenditure. As of recent reports, there are over 9,0009,000 Jan Aushadhi Kendras operational across India, and the scheme has saved citizens an estimated ₹10,000 crore₹10,000 crore annually. This quantitative impact is crucial for exam answers.

The scheme is a direct manifestation of the government's commitment to the Directive Principles of State PolicyDirective Principles of State Policy, particularly Article 4747, which mandates the state to improve public health. It aligns with the broader goal of achieving universal health coverage and ensuring that essential medicines are a public good, not just a commodity.

UPSC examiners often test the understanding of the scheme's objectives, its operational model (PMJAKs), the quality assurance mechanisms, and its impact on affordability and accessibility. They might ask about the difference between Jan Aushadhi and branded generics, or the challenges faced by the scheme, such as supply chain disruptions or ensuring consistent quality from all suppliers.